Why did BCAL Diagnostics (ASX:BDX) develop the new BREASTEST Monitor blood test?

BCAL Diagnostics (ASX:BDX) developed the test to address a clinical gap in post-treatment monitoring, as local breast cancer recurrence affects up to 15% of patients.

What are the preliminary clinical results for the BCAL Diagnostics (ASX:BDX) surveillance test?

In initial evaluations of women aged 50 and older, the test from BCAL Diagnostics (ASX:BDX) achieved a 91% sensitivity rate and a 95% negative predictive value. The diagnostic tool correctly identified 20 out of 23 confirmed local recurrence cases within a held-out test set of 100 patient samples.

How did the share price of BCAL Diagnostics (ASX:BDX) react to the announcement?

Following the product development announcement, the BCAL Diagnostics (ASX:BDX) share price remained unchanged at $0.12.

What are the next pipeline and validation timelines for BCAL Diagnostics (ASX:BDX)?

BCAL Diagnostics (ASX:BDX) is seeking additional breast cancer patients, including women under 50 years of age, to participate in further clinical validation studies. The company stated that these additional validation studies must be completed before the commercial launch of the test.

What does this development mean for the broader market strategy of BCAL Diagnostics (ASX:BDX)?

The new test expands the diagnostics platform of BCAL Diagnostics (ASX:BDX) into the global breast cancer surveillance market, which the company notes is projected to reach $4.5 billion by 2030. It complements the existing product portfolio of BCAL Diagnostics (ASX:BDX).

Image for illustrative purposes only. Not a real photo.

BCAL Diagnostics develops breast cancer test with 91% sensitivity

Written by Liezl GambePublished Jun 18, 2026, 5:28 AM

BCAL Diagnostics has developed a new blood test to evaluate local breast cancer recurrence.
Preliminary findings show the diagnostic tool achieved a 91% sensitivity rate during initial evaluations.
The company intends to position the test as a standalone tool to address post-treatment surveillance needs.

Australian healthcare company BCAL Diagnostics (ASX:BDX) has developed a diagnostic blood test that achieved 91% sensitivity for detecting breast cancer recurrence.

This development addresses a clinical gap where local disease recurrence affects up to 15% of women following cancer treatment.

Preliminary study findings showed that the test correctly identified 20 out of 23 confirmed local recurrence cases.

The company stated that it intends to eventually position the test as a standalone surveillance tool.

Following the announcement, the BCAL Diagnostics share price was unchanged at $0.12.

BCAL previously launched another blood test to assist in the evaluation of breast disease for women with dense breasts.

The company also holds an exclusive licence to distribute multi-cancer early detection tests in Australia and New Zealand.

BCAL Diagnostics develops breast cancer test with 91% sensitivity

Frequently asked questions

Assets related to this article